Literature DB >> 18596026

An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.

Lorenzo Melchor1, Javier Benítez.   

Abstract

Do breast cancer tumours have a common cell origin? Do different breast cancer molecular phenotypes arise from distinct cell types? The studies we have performed during the last few years in familial breast tumours (BRCA1, BRCA2 and non-BRCA1/2) widen questions about the development of sporadic breast cancer to hereditary breast cancer. Array-comparative genomic hybridisation (CGH) studies show universal genomic aberrations in both familial and sporadic breast cancer subtypes that may be selected in the breast tumour development. The inactivation of BRCA1 seems to play a critical role in oestrogen receptor (ER)-negative cancer stem cells (CSCs), driving the tumour development mostly towards a basal-like or, in some cases, to a luminal B phenotype, but other carcinogenetic events are proposed to explain the remaining tumour subtypes. The existence of common genomic alterations in basal-like, ERBB2 and luminal B breast tumours may suggest a common cell origin or clonal selection of these tumour subtypes, arising from an ER-negative CSC or from a progenitor cell (PC). Finally, specific genomic aberrations in ER-positive tumours could provide cellular proliferation advantages when the cells are exposed to oestrogen. We propose a combination of the CSC hypothesis (for the carcinogenesis processes) and the clonal selection model (in terms of tumour development). We uphold that the basal-like-, ERBB2- and luminal B-sporadic and familial tumour subtypes have an ER-negative breast stem/PC origin, whereas luminal A tumours arise from an ER-positive PC, supporting a hierarchical breast carcinogenesis model, whereas crucial genomic imbalances are clonally selected during the tumour development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596026     DOI: 10.1093/carcin/bgn157

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  21 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 2.  What can we learn about disease etiology from case-case analyses? Lessons from breast cancer.

Authors:  María Elena Martínez; Giovanna I Cruz; Abenaa M Brewster; Melissa L Bondy; Patricia A Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-24       Impact factor: 4.254

Review 3.  Stemming resistance to HER-2 targeted therapy.

Authors:  Philippe L Bedard; Fatima Cardoso; Martine J Piccart-Gebhart
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-03-04       Impact factor: 2.673

4.  Breast cancer subtypes and previously established genetic risk factors: a bayesian approach.

Authors:  Katie M O'Brien; Stephen R Cole; Lawrence S Engel; Jeannette T Bensen; Charles Poole; Amy H Herring; Robert C Millikan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-31       Impact factor: 4.254

5.  P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis.

Authors:  Robin Fuchs-Young; Stephanie H Shirley; Isabel Lambertz; Jennifer K L Colby; Jie Tian; Dennis Johnston; Irma B Gimenez-Conti; Lawrence A Donehower; Claudio J Conti; Stephen D Hursting
Journal:  Breast Cancer Res Treat       Date:  2010-12-30       Impact factor: 4.872

6.  Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women.

Authors:  Ming-xi Jing; Xiao-yun Mao; Chao Li; Jing Wei; Chong Liu; Feng Jin
Journal:  Tumour Biol       Date:  2011-04-06

Review 7.  The complex genetic landscape of familial breast cancer.

Authors:  Lorenzo Melchor; Javier Benítez
Journal:  Hum Genet       Date:  2013-04-05       Impact factor: 4.132

8.  The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.

Authors:  Rebecca E Nakles; Bhaskar V S Kallakury; Priscilla A Furth
Journal:  Am J Pathol       Date:  2013-05-08       Impact factor: 4.307

9.  Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells.

Authors:  Kara L Britt; Howard Kendrick; Joseph L Regan; Gemma Molyneux; Fiona-Ann Magnay; Alan Ashworth; Matthew J Smalley
Journal:  Breast Cancer Res       Date:  2009-04-23       Impact factor: 6.466

10.  Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis.

Authors:  R Fernández-Ramires; X Solé; L De Cecco; G Llort; A Cazorla; N Bonifaci; M J Garcia; T Caldés; I Blanco; M Gariboldi; M A Pierotti; M A Pujana; J Benítez; A Osorio
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.